BioNexus Gene Lab's gross profit for the
three
months ended in Sep. 2024 was $0.33 Mil. BioNexus Gene Lab's gross profit for the trailing twelve months (TTM) ended in Sep. 2024 was $1.25 Mil.
BioNexus Gene Lab had a gross margin of 12.43% for the quarter that ended in Sep. 2024 => No sustainable competitive advantage
During the past 6 years, the highestGross Margin % of BioNexus Gene Lab was 44.09%. The lowest was 11.52%. And the median was 14.39%.
Warning Sign:
BioNexus Gene Lab Corp gross margin has been in long-term decline. The average rate of decline per year is -10.7%.
BioNexus Gene Lab Gross Profit Historical Data
The historical data trend for BioNexus Gene Lab's Gross Profit can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of BioNexus Gene Lab's Gross Profit
For the Specialty Chemicals subindustry, BioNexus Gene Lab's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioNexus Gene Lab's Gross Profit Distribution in the Chemicals Industry
For the Chemicals industry and Basic Materials sector, BioNexus Gene Lab's Gross Profit distribution charts can be found below:
* The bar in red indicates where BioNexus Gene Lab's Gross Profit falls into.
BioNexus Gene Lab Gross Profit Calculation
Gross Profit is the different between the sale prices and the cost of buying or producing the goods.
BioNexus Gene Lab's Gross Profit for the fiscal year that ended in Dec. 2023 is calculated as
Gross Profit for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.25 Mil.
Gross Profit is the numerator in the calculation of Gross Margin.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
BioNexus Gene Lab had a gross margin of 12.43% for the quarter that ended in Sep. 2024 => No sustainable competitive advantage
BioNexus Gene Lab Gross Profit Related Terms
Thank you for viewing the detailed overview of BioNexus Gene Lab's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.
BioNexus Gene Lab Corp through its wholly owned subsidiary, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries in the Southeast Asia region. These countries include Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. In addition, the Company is in the business of developing and providing safe, effective, and non-invasive liquid biopsy tests for the early detection of biomarkers that it believes are linked to diseases to minimize treatment costs and improve patient management. Its non-invasive blood tests provide analysis of changes in RNA to detect the potential risk of 11 different diseases.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
BGLC has been successfully added to your 